Comments The study is the first interventional study on IGF-1 treatment in children with CD. The authors used a mathematical model to determine the dose of rhIGF-1 that maintained serum IGF-1 level within the physiological range. The dosing schedule which reflects the age dependency of circulating IGF-1 in normal children and the state of GH resistance in children with CD was 21 + 1 μg/kg/PCDAI point for the 10-to 12-year-olds and 41 + 1.4 μg/kg/PCDAI point for the 12-to 14-year-olds. Growth-promoting therapies such as rhGH, rhIGF-1 or the two in combination are currently being explored as possible methods of promoting growth in children with disease-related growth retardation and this study may assist in the design of future clinical trials. The study also showed that the extent of protein-losing enteropathy measured by fecal α 1 -antitrypsin level did not alter IGF-1 or IGFBP-3 levels. Administration of rhIGF-1 to children with a decreased level of IGFBP-3 may lead to increased free IGF-1 but this was not evaluated in this study. However, the authors stated that the level of IGFBP-3 was not severely depressed as it remained with 2 SDs of normal even in the most severely affected cases.
Nutrition and Growth
Clinical progress in the two years following a course of exclusive enteral nutrition in 109 paediatric patients with Crohn's disease Comments This relatively large retrospective study confirms previous observations that despite disease remission (as assessed by global patient assessment in combination with clinical parameters), improvement in weight and short-term improvement in height velocity, the use of EEN may not be associated with a sustained improvement in HtSDS over the longer term. Thus, there is a need to continue investigating novel forms of growth promotion in these children. The authors also point out that improvement in weight and inflammatory markers was already present by 4 weeks, thus questioning the need for 8 weeks of EEN.
Biologics and Growth

Partial normalization of pubertal timing in female mice with DSS colitis treated with anti-TNF-α antibody
DeBoer MD, Steinman J, Li Y Division of Pediatric Endocrinology, University of Virginia, Charlottesville, VA, USA
J Gastroenterol 2012; 47: 647-654
Background: Delayed puberty is a common concern for children with IBD, and especially CD, and is associated with inadequate growth, defective bone mineralization and poor self-esteem. Currently, biologic agents are the mainstay in children with more severe forms of IBD resistant to conventional treatment. Biologic agents are engineered proteins which selectively neutralize or block the effects of different cytokines. One of the commonly used agents is infliximab, a monoclonal antibody to tumor necrosis factor-α (TNF-α). Some studies have reported that the use of infliximab is associated with improved growth in children with CD whose disease improves. However, whether infliximab treatment affects the timing of puberty is not yet clear. This experimental study was designed to determine whether TNF-α antibodies normalize pubertal progress and whether infliximab causes any change in the function of the hypothalamic-pituitary-gonad (HPG) axis in female mice with induced colitis. Methods: Dextran sodium sulfate (DSS) colitis was induced in 23-day-old female mice and the treatment groups were divided into three groups: control + TNF-α antibodies, DSS-induced colitis + control antibodies, and DSS-induced colitis + TNF-α antibodies. All groups were monitored for the timing of vaginal opening until day 33 of life, when they were euthanized for serum and colon collection. Results: Timing of vaginal opening in DSS + TNF-α and control + TNF-α antibodies was similar and occurred earlier compared with DSS + control antibody group. Also, DSS + TNF-α antibody had a higher LH level after GnRH stimulation and lower systemic interleukin-6 compared to the DSS + control antibody group. No differences were observed in weight gain, growth, or colon histological inflammatory scores between the three groups over the course of the experiment.
Conclusion:
The authors demonstrated that treatment with monoclonal antibodies to TNF-α was associated with partial normalization in the timing of pubertal onset in female mice with DSS colitis.
Comments The authors of this study have previously shown that female mice with DSS colitis had a later timing of vaginal opening than food-restricted mice of the same body weight. In the current study they confirmed this finding and showed that this difference persisted in spite of similar weight gain and circulating leptin. The only difference was in the extent of inflammation as assessed by circulating cytokines and gut inflammation. The raised levels of LH in DSS colitis model treated with TNF-α antibodies are intriguing and the authors did not have a good explanation for this. This effect was not observed in the control group suggesting that colitis may sensitize the hypothalamic pituitary axis to GnRH stimulation. The hypothalamic-pituitary-gonadal axis is under negative feedback control by circulating sex steroids and it is possible that the increased responsiveness to GnRH may reflect direct suppression of sex steroid synthesis at the level of the peripheral steroid-secreting organs by the cytokines. The investigators suggest that in humans the use of biologics may be associated with pubertal progress or increased gonadal activity, but this requires further investigation.
Long-term outcome of tumor necrosis factor-α antagonist's treatment in pediatric Crohn's disease
J Crohn Colitis 2013; 7: 369-376
Background: The efficacy of infliximab for both induction and maintenance of moderate to severe pediatric CD is widely accredited. However, its effect on optimization of linear growth seems to be variable. Some studies demonstrated a short-term increase in height velocity during infliximab treatment while others showed no significant change during a similar follow-up time. One of the secondary outcomes of this study was to examine the long-term outcome of anti-TNF-α on the growth of children with IBD. Methods: In this multicenter study, 102 IBD children who received anti-TNF-α therapy at a mean age of 13.4 ± 3.9 years for a median duration of 15 (2-90) months were retrospectively studied. The authors recorded long-term response rates, predictors for loss of response as well as the effect of treatment on anthropometric parameters. Results: A short-term beneficial response on disease was observed in 91/102 (89%) of the cohort following induction and a prolonged response for more than 6 months occurred in 84/102 (84%). The mean BMI z-score improved significantly in responders (-0.8 to -0.4, p = 0.04) compared to non-responders. A tendency towards enhanced growth velocity was also found in responders compared to non-responders. Only male responders showed a significant increase in height velocity during treatment.
Conclusion:
In agreement with the current literature, the study showed that biologic agents were effective and safe in the long term. Furthermore, the clinical response was associated with improved weight and BMI.
Comments The ability of biologic agents to improve growth and growth failure in children with CD continues to be an area of controversial debate. The growth data from this study needed to be interpreted with caution because of a lack of pubertal growth information. In addition, a large proportion of the cohort patients were on glucocorticorticoids which may also have affected growth.
The effects of anti-TNF-α treatment with adalimumab on growth in children with Crohn's disease
J Crohn Colitis 2012; 6: 337-344
Background: Adalimumab is a humanized anti-TNF therapy that has been shown to be effective for induction and maintenance of remission for adults with Crohn's disease (CD). Clinical studies of adalimumb in children are relatively limited; no studies have yet examined the effect of adalimumb on growth. In this multicentre retrospective study the authors assessed the influence of adalimumab therapy on growth and disease activity in children with CD. Methods: Growth and disease activity of 36 children with CD who started adalimumab at a median age of 14.7 years (11.3-16.8) were collected at 6 months before (T-6), at baseline (T0) and 6 months after (T+6) starting adalimumab. Results: Remission occurred in 28/36 children (78%). 15 children (42%) demonstrated improvement in their growth, median change in height z-score (ΔHtSDS) increased from -0.3 at T0 to +0.3 at T+6. The improvement in ΔHtSDS was more likely in children who achieved remission (ΔHtSDS) increased from -0.2 at T0 to +0.2 at T+6. In those in pubertal Tanner stage II-III, median ΔHtSDS improved from -0.4 at T0 to +0.2 at T+6. In those with immunosuppression background, ΔHtSDS increased from -0.2 at T0 to +0.1 at T+6. When adalimumab was indicated because of infliximab allergy, median ΔHtSDS increased from -0.3 at T0 to +0.3 at T+6. The change in height SDS also improved in children who were on prednisolone when starting adalimumb.
Conclusion:
This study showed that the clinical response to adalimumab therapy was associated with an improvement in linear growth in children with CD.
Comments
The results of this study suggest that the use of adalimumab can be helpful in terms of linear growth improvement in children with CD. By looking at the results, growth improvement in this cohort may be credited to both controlling of inflammation and progression of puberty, as the increase in ΔHtSDS was more likely in those who achieved remission as well as in pre-puberty and in-puberty children. However, it is uncertain yet from this study and other studies whether this short-term improvement in linear growth is maintained over a longer period and whether there is an improvement in final height, which is the ultimate objective in any patients with growth impairment. It is anticipated that future efforts will be directed to also explore the effect of biologics on final height in adults with childhood-onset CD.
Growth in children receiving contemporary disease-specific therapy for Crohn's disease Background: Data from recent studies have shown that despite improvements in therapy, nutrition and a decrease in the use of glucocorticoid (GC) therapy, there is a persisting concern that poor growth still exists. The mechanism of growth failure in children with IBD is multifactorial and includes poor nutrition, chronic inflammation, and the prolonged use of steroids. These factors interfere with growth through disturbance of the GH-IGF axis at the peripheral or central level.
Growth improvement through manipulation of the GH-IGF axis may offer a therapeutic option which needs further exploration. Nonetheless, the assessment of prevalence of growth impairment in children receiving advanced therapy may be needed before launching studies of alternative forms of growth-promoting endocrine therapy.
Methods:
The study is a retrospective analysis of growth and therapy data of 116 children with CD (mean age at diagnosis 10.8 years), at time of diagnosis (T0), at 1 (T1), 2 (T2) and 3 years (T3) after diagnosis and at maximum follow-up (MF).
Results: There was a significant reduction in mean height z-score (HtSDS) between T0 and T1. No significant difference was observed in HtSDS after that. Moreover, no change was observed in mean ΔHtSDS at T1, T2, T3 and MF. However, there was a significant increase in mean HVSDS (10th, 90th) from -1.4 (-7.4 to 7.4) to -0.6 (-7.5 to 6.1) between T1 and T2, from -0.6 to -0.1 between T2 and T3 and from -0.1 to 0.6 between T3 and MF. There was a negative association between HtSDS and the use of prednisolone, azathioprine, methotrexate and weight SDS. A negative association was also found between ΔHtSDS and use of prednisolone and a positive association between HVSDS with age and WtSDS.
Conclusion:
The authors concluded that short stature and slow growth continue to be encountered in a subgroup of children with CD despite advances in therapy. They suggest that change in HtSDS may be a more robust parameter in children with chronic disease when there is a high prevalence of children of peripubertal age.
Comments Although the majority of children with CD are not particularly short and there is an improvement in growth during the first year after diagnosis, this study provides clear evidence that despite advances in therapy, short stature and slow growth continue to be encountered in a subgroup of children with CD. The mean HtSDS of our population as well as the percentage of children with HtSDS <-2 were similar to those reported in other recent studies. Our observation that HtSDS did not improve in spite of significant improvement in HVSDS is similar to the findings in previous reports and may suggest that the reduction in growth deceleration, as reflected by improving HV, is not sufficient to improve overall height but simply prevents any further deterioration in height. Many studies of growth in children with a complex condition such as IBD explore the association between growth and disease factors, including drug therapy. The study highlights that investigation of such associations need a long follow-up as the choice and duration of therapy for IBD depends on the acute presentation and subsequent progress.
Overall Commentary :
Over the last year a number of studies have evaluated growth impairment as well as the outcomes of therapeutic intervention aimed to improve growth in children with IBD. Given the persistent deficit in height in children with IBD, there is a need for further improvements in therapy that focus on growth. Clinicians and investigators need to pay more attention to puberty aspects, especially in this group of conditions which often present during the peripubertal period, since a substantial amount of growth occurs during puberty. It has been suggested that pubertal development and progress is not significantly affected in children with IBD treated with the current therapeutic modalities. It would, therefore, be useful to investigate whether growth during puberty is optimal or not. The studies that have been performed over the last year also highlight the large variation amongst investigators as to how they describe growth and pubertal progress. There is a need for greater consistency and harmony in reporting results. Finally, these studies cannot be performed without close collaboration between a multidisciplinary group of experts from fields that include anthropometry, endocrinology, nutrition medicine and gastroenterology.
dicating a strong association between WAP at age 4 years and height throughout life. Each higher WAP group had incrementally better FEV1% predicted throughout the period of observation, but the greatest difference in FEV1% predicted occurred between the WAP <10% and 10-25%. 
Aims:
The primary outcome of the study was to assess the longitudinal growth pattern in a large cohort of French patients with CF and to determine the extent to which growth during puberty affects final height. In addition, the study aimed to explore the potential relationships between growth, nutritional status and respiratory function in children with CF.
Methods:
The study included the data from the French CF registry collected between 1999 and 2004. Eight groups of patients aged 8-15 in 1999 were selected. Individual characteristics (age, height, weight) and lung function, evaluated by FEV1 were recorded. The means of individual heights in each age group were used to construct the height curves by sex.
Results:
The study evaluated a sample of 729 children with CF among the 1,108 children born between 1984 and 1991 and followed by the registry from 1999 to 2004. For the 331 girls the height curve was very close to the median curve until the age of 12, when the curve descended to the -1 SD reference curve. The mean z-score of mean height was -0.32 at age 8 and -0.53 at 11 years. The z-score then decreased to a minimum of -0.88 at age 15, and remains under -0.50 after this age. The final height of 160.4 cm was reached at age 19, much later than the age of final height in the reference population which is attained at age 16. The age of pubertal onset was similar to the reference, but the peak height velocity (PHV), although occurring at the same age as in reference girls, was lower, and the pubertal spurt accounted for 16.7% (compared to 18.6% in healthy girls) of the final adult height. The mean height curve for boys (n = 389) showed normal growth until age 14, and then downgraded to the -1 SD of the reference curve. The final height in boys was reached at age 19, similar to the age of final height in healthy boys. The mean final height in boys with CF was less than that in the overall population (z-score -0.73). The age of pubertal onset was similar to that in reference boys (13 years), but the PHV was lower and the pubertal spurt accounted for 15.5% 
Conclusions:
The longitudinal follow-up of this French cohort of patients showed that the onset of puberty in children with CF was comparable to healthy children, but PHV was decreased and contributed less to the final adult height. The final height was significantly lower than that in the reference population, even though it remained within the normal range. Growth and lung function were not correlated in boys, however there was a weak but significant correlation between lung function and growth in girls, which might be explained by the greater rest energy expenditure in girls than in boys after the pubertal spurt. Aims: Using the US CFF Registry data of patients' anthropometry and follow-up the authors evaluated the relationship between prepubertal and pubertal growth velocity (timing and magnitude) and final adult height in children with CF. Methods: Using height measurements, the authors constructed puberty height velocity (PHV) curves for CF patients. Using longitudinal standards of PHV for healthy North American children developed by Tanner and Davies, PHV was classified into normal (PHV neither delayed nor attenuated), delayed (PHV delayed but not attenuated), attenuated (PHV attenuated but not delayed), and delayed and attenuated. CF phenotypes, prepubertal nutritional status and genetic height potential were introduced as variables.
Pubertal height velocity and associations with prepubertal and adult heights in cystic fibrosis
Results: Of the 4,198 individuals with CF born in 1984-1987, 309 died, 951 were lost to follow-up before age 18 years, and 1,076 had <3 height measurements per year during age 10-18 years, leaving 1,862 patients to include in the study. PHV in children with CF occurred later (0.5 years later in boys and 0.6 years later in girls) and showed reduced magnitude (1.1 cm less in boys and 1.3 cm in girls).
Results from fitting individual curves revealed that PHV was normal in 60.3%, delayed in 9.4%, attenuated in 20.8%, and delayed and attenuated in 5.3%. In the remaining 4.2%, PHV could not be ascertained. More boys had normal PHV than girls, p = 0.002. PHV magnitude and total gain from height take-off at puberty was different and depended on whether the puberty was delayed and/or attenuated. Considering parental height, 80% of boys with CF and 77% of girls with CF had adult heights below their average parental height percentiles. Multivariate analyses revealed PHV age, PHV magnitude, and prepubertal height at age 7 years were stronger predictors of adult height (all with p < 0.001). Specifically, later PHV was associated with smaller magnitude of PHV but greater adult height. Larger PHV magnitude was associated with greater adult height after adjusting for PHV age. Conclusions: Using a novel, semi-parametric growth curve model, this study showed that 23% of boys with CF and 30% of girls with CF had impaired PHV magnitude that was below the 5th percentile of healthy children. Besides that, children with CF born in the mid-1980s experienced delayed pubertal PHV compared with healthy children and had lower final height, as the majority (80% of boys and 70% of girls) did not reach their genetic potential. Prepubertal height at age 7 years was found to be a strong determinant of adult height in both sexes. Since the greatest likelihood of achieving optimal growth at age 6 years is through maximizing weight gain during the first years of life, this study further emphasize the importance of maintaining adequate growth through pre-adolescence.
Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study
Stephenson AL [1] [2] [3] [4] Aims: The aim of the present study was to investigate the nutritional status evolution during a longterm follow-up of a CF cohort followed at the Adult CF Clinic in Toronto. Methods: The study examined nutritional status assessed as WHO BMI and the relationship between BMI and lung function in 909 individuals with CF. FEV1 expressed as a percentage of the normal predicted values for height and sex (FEV1% predicted), height and weight were measured at every clinic visit. The subjects were classified in 4 cohorts based of birth year (<1960, 1960-1969, 1970-1979 , >1979) and the BMI was parted according to the year the clinical measurements were taken (<1990, 1991-1999, >2000). Due to the skewed distribution of BMI and age, these variables were log transformed. Results: The study cohort study included 909 individuals followed from 1985 to 2011. The average BMI increased from 20.7 ± 2.7 before 1990 to 22.3 ± 3.4 in the most recent decade (2000-2011). The proportion of underweight individuals has also decreased from 20.6% before 1990 to 11.1% in the most recent decade. The proportion of adequate-weight subjects slightly decreased (72.4% in 1980s, 72.6% in the 1990s, to 70.5% in the 2000s), whereas the proportion of overweight/obese subjects increased from 7.0% in the 1980s to 15.8% in the 1990s and to 18.4% in the most recent cohort (p trend <0.001). Multivariable models showed that, overall, BMI increased by 0.4%/year from 1985 to 2011. The rate of BMI increase in PS subjects was much greater than in PI subjects (3.8% compared with 0.4%/year, respectively; p < 0.001). The BMI of 651 individuals evaluated between 2000 and 2011 showed that 17% of CF subjects were underweight, 60% had adequate weight, 18% were overweight, and 3.8% were obese. After adjustment for age, height, sex, CFRD, pancreatic status, and birth cohort, lung function showed improvement as BMI increased. The magnitude of FEV1 improvement was different across BMI categories: in the underweight group, a 10% increase in BMI resulted in a 4% relative increase in FEV1, in the subjects within adequate range BMI there was a 5% relative increase in FEV1, and in those overweight there was a 2% increase in FEV1. On average, FEV1 decreased at a rate of 1%/year, and there were no significant differences in the rate of FEV1 decline in the three BMI categories. Other significant independent predictors of FEV1, identified in the multivariable model, included age [older age was associated with lower FEV1% (predicted; p < 0.001), pancreatic status (PS subjects had higher FEV1% predicted), and the presence of CFRD (CFRD subjects had lower FEV1% predicted]. Conclusion: This longitudinal, population-based cohort showed a significant shift over a 25-year period in the distribution of BMI in adults with CF. Within a contemporary cohort of individuals with CF, fewer individuals were malnourished and more individuals were overweight compared with 20 years earlier. The study showed that improvements in nutritional status were associated with improvements in lung function which was better in the average BMI subgroup of the CF population.
Stunting is an independent predictor of mortality in patients with cysticbone mineral content (BMC) and density (BMD) were obtained by dual-energy x-ray absorptiometry (DXA). Results: 24 children (31%) were malnourished, as defined by the FFMI and/or BMI% criteria; 16% had low BMI% and low FFMI; 14% had normal BMI and low FFMI (hidden depletion), and 1% had low BMI% and normal FFMI. Overall, 30% of patients were characterized by FFM depletion. The sensitivity of BMI% for detecting FFM depletion was 52% and the specificity was 98%. BMC (percentage of normative data) was reduced in the group with low BMI% and FFMI (p < 0.001) and in the hidden FFMI depletion group (p < 0.05) as compared to the normal BMI% and FFMI group. BMD of the whole-body and spine z-score were lower (p < 0.01) in those with low BMI% and FFM as compared to normal BMI% and FFM. Below the 20th BMI% the percentage of patients with a BMD z-score <-1 SD increased steeply whereas no differences were found in the percentage of patients with a reduced BMD in the 20-49th BMI% group. FEV1 and forced vital capacity (FVC) were reduced in both the hidden FFM depletion group (p < 0.05) and the low BMI% and FFM group (p < 0.01). FEV1 was significantly correlated with FFM (% norm, r = 0.39, p < 0.001) and FM (% norm, r = 0.30, p < 0.01) but not with FM/FFM (r = 0.21). With the decline in BMI%, there was also a gradual reduction in mean FEV1. Below the 20th BMI%, mean FEV1 dropped below 80% predicted, a threshold for abnormal lung function in children with CF. Investigation of the BMI% cut-off point that would predict FFM depletion and poor clinical outcome showed a gradual reduction in FFM% with the decline in BMI%. Below the 20th BMI%, there was a drop in FFM% below 90% of normative values which corresponds to FFMI <5th percentile. 57% of the patients in the 10-20th BMI% group had FFM depletion, compared to 18% in the 20-30th BMI% group. Nearly all patients (92%) with BMI% <10 were FFM depleted. Conclusions: FFM depletion in children with CF is prevalent and is poorly detected when using the 10% BMI cut-off, indicating that a large share of patients with hidden FFM depletion would have been missed when malnutrition was defined only by these criteria. Low FFM values were associated with reduced lung function and bone mineral loss indicating the clinical importance of measuring body composition in children with CF. subjects was -0.58 (range -4.61 to 2.46), which corresponded to the 28th CDC percentile; the median weight z-score was -0.42 (range -6.23 to 2.38), which corresponded to the 34th CDC percentile. The median BMI z-score was -0.07 (range -3.89 to 2.30), which corresponded to the 47th CDC percentile. There were no significant differences in the average BMI z-score between monozygous twins and siblings and dizygous twins and siblings. All covariates in the model remained independent predictors of BMI-z5to10 in the multivariate models. Adjusted BMI z-score phenotypes were generated for female sex, birth cohort, PI, and history of MI (BMI-zadj ) and in a second analysis for BMI-zadj plus for FEV q6to10 (BMI-zadjFEV ), which considered the influence of lung function on BMI for subsequent heritability and linkage analyses. There was a high degree of concordance for BMI in individuals who shared 100% of genes, for monozygous twins (0.80-0.85 for 58-65 pairs). The dizygous twin-only groups had lower correlation coefficients (0.58-0.66 for 21 dizygous twin pairs; 0.41-0.57 for 13 same-sex, dizygous twin pairs), which indicated a lower concordance in this group of twins who shared, on average, 50% of genes. Correlation coefficients for the dizygous twin and sibling group were 0.5 (0.25-0.31 for 122-148 pairs). Linkage results for individuals with PI ( BMI-zadj-PI ; 358 sibling pairs) revealed 2 prominent genome-wide significant peaks on chromosomes 1p36.1 (LOD: 5.3) and 5q14 (LOD: 5.1). Restriction of the analysis to the 219 sibling pairs who were homozygous for the F508del mutation (BMI-zadj-F508del ) preserved the peak on chromosome 1p36.1 (LOD: 4.6) but decreased the evidence for linkage on chromosome 5q14 (LOD: 3.4). Adjustment of BMI for lung function (BMI-zadjFEV-PI ; 350 sibling pairs) decreased the LOD score for the locus on chromosome 1p36.1 (LOD: 3.4) but increased the evidence for linkage at an adjacent region from chromosome 1p31-22 (LOD: 2.4); linkage on chromosome 5q14 (LOD: 5.2) was unaffected. Quantitative trait locus (QTL) heritability at 1p36.1 and 5q14 after correction for potential bias represented ≥ 16% and ≥ 15% of the BMI variance.
Conclusions: This is the first study on the nutritional status of young twins and siblings with CF which shows that genes other than CFTR influence the variation in BMI. Specifically, the results from this study suggested that modifier genes located at the 1p36.1 locus influence both nutritional status and lung function, whereas chromosome 5q14 encompasses a gene that modifies nutritional status that is independent of lung disease severity.
Oral calorie supplements for cystic fibrosis
Smyth RL 1 , Walters S height percentile, weight for height or body mass index (BMI) (primary outcomes). There were no differences between intervention (oral supplementation) and non-intervention groups with regard to secondary outcomes including total (oral or supplemented) intake of calories, protein, fat, feeding behavior or measures of quality of life. Forced expiratory volume in 1 s (FEV1) (% predicted) was significantly decreased at 3 months in the control group but not at 6 and 12 months. The change in forced vital capacity (FVC) (reported only by Poustie et al. [5] ), was not significantly different between groups at 3, 6 or 12 months. The single study [5] that evaluated the presence of adverse effects of oral supplements reported no differences on diarrhea, appetite, abdominal bloating, episodes of distal intestinal obstruction syndrome and any other adverse effects between intervention and non-intervention groups.
Conclusions: This systematic review showed that short-term use of oral supplements did not improve the nutritional status in children with CF and mild to moderate malnutrition. Since no difference in nutritional status or lung function was reported with the use of oral nutrition supplements, one may conclude that dietary advice alone is also a satisfactory approach to the management of people with CF and moderate malnutrition. This systematic review raises questions about the utility of the practice of prescribing oral nutrition supplements for the nutritional care and rehabilitation of children with CF. 
Nutritional outcomes following gastrostomy in children with cystic fibrosis
Aims:
The primary aim of the study was to evaluate the ability of nutrient supplementation using a gastrostomy tube (GT) to improve nutritional status in children with CF and low BMI. Furthermore, the study evaluated the effects of GT placement and supplemental nutrition on lung function, number of hospitalizations for pulmonary exacerbation and complications during and after GT placement.
Methods: This retrospective study evaluated 40 patients (20 children with GT and 20 controls) 2-20 years old with data at least 1 year after GT placement. Each one of the 'cases' (children with GT) was pair-matched with a child with CF who did not have a GT ('controls'). The cases and controls were matched for age ± 2.5 years, sex, pancreatic status, BMI percentile ± 10% and, when available, FEV1 ± 20%. Data on GT placement technique, complications during and after GT placement and nutritional supplementation through GT were collected in the 'cases' group. For the controls, use of oral nutritional supplementation, appetite stimulant and/or a gastroenterology (GI) referral for GT placement at any time during the 1-year follow-up period were recorded. Nutritional and lung function data (including height, weight, BMI, and percent predicted FEV1) were obtained at the enrollment visit, 6-month (±3 months) and 1-year (±3 months) follow-up. The number of hospitalizations required for pulmonary exacerbation during the 1-year follow-up period was also recorded.
Results: GT placement was without complications in 15/20 and whole protein formula was given to 18/20 children. GT delivered about 50% of the 110-200% dietary reference intake recommendation. The whole GT supplementation was delivered continuously overnight. A dose of pancre-atic enzymes was given at the beginning and the end of the feeds. At the 6-month follow-up visit, 7 (35%) of the cases and 1 (5%) of the controls reached BMI ≥ 50th percentile (p < 0.04). The patients supplemented by GT were almost 10 times as likely to reach BMI ≥ 50th percentile at 6 months compared to the control group (OR = 9.70; 95% CI 1.05-484.7). At 1-year follow-up, 8 (40%) of the cases and 3 (15%) of the controls had reached BMI ≥ 50th percentile (p < 0.16) (OR = 3.65; 95% CI 0.69-25.86). The mean ± SD BMI was significantly better compared to controls (p < 0.001) at 6 months, but not at 12 months. The mean weight z-score improved significantly from the baseline compared to controls at 6 months (p < 0.001) and 12 months (p < 0.01) but the change in mean height z-score was comparable between cases and controls. At 6 months, the mean ± SD BMI and mean weight z-score in the GT group improved from the baseline compared to controls (p < 0.001), while there was no difference in mean height z-score between the two groups. At 1 year, the cases still had a higher mean BMI z-score than the controls, but the difference from baseline no longer achieved statistical significance. The change in mean weight z-score was still statistically significant (p < 0.01), but the change in mean height z-score was again comparable. The groups were similar in the change in mean predicted FEV1 from baseline to 6 and 12 months and there were no statistically significant differences between the cases and controls in the number of hospitalizations required for pulmonary exacerbation. By 1 year, 1 child was no longer receiving supplemental nutrition via the GT. At 1 year, 12/20 controls were advised to take oral supplements and 6 were prescribed an appetite stimulant. One patient was referred for GT placement.
Conclusions:
In this retrospective study, nutritional support using supplemental feedings via a GT was shown to improve weight gain in patients with CF. According to the current study, children with CF who had a BMI <50th percentile for age and received a GT were almost 10 times as likely to reach BMI ≥ 50th percentile at 6 months compared to matched patients who did not receive a GT and were 3.65 times as likely to reach BMI ≥ 50th percentile by 12 months. The conclusions are weakened by the fact that these changes did not reach statistical significance.
Recombinant growth hormone therapy for cystic fibrosis in children and young adults
compared with no treatment; one study had three treatment arms: placebo, standard dose (0.3 mg/ kg/week) and high dose (0.5 mg/kg/week). Pulmonary function reported as FEV1 or FVC [6] showed no evidence of an effect from rhGH treatment. Height and weight were not significantly changed by rhGH treatment [9] , but height velocity showed a significant difference in favor of rhGH, MD 2.10 (95% CI 0.54-3.66). Fasting blood glucose at 6 months [6] showed a significant increase in the rhGH treatment group, MD 12.40 (95% CI 3.76-21.04), however the difference in postprandial glucose levels was not significant, MD 12.10 mg/dl (95% CI -7.18 to 31.38) (0.54-3.66). Muscle strength and the number of pulmonary exacerbations were also no different in the rhGH treatment. Conclusions: rhGH treatment in children with CF achieved modest improvements in anthropometric measures (height, weight, height and weight velocity and lean tissue mass). At this stage, the question of whether this improvement translates into better pulmonary outcomes, reduction in morbidity and improved quality of life has not been answered from the available evidence, due to scarcity of data.
Comments Cystic fibrosis (CF) is a common autosomal recessive genetic disorder, diagnosed in approximately 1 in 2,500 births, more often in populations of Caucasian descent. The gene, the CF transmembrane regulator (CFTR) located on chromosome 7, encodes a protein that functions as a cAMP-regulated chloride channel and controls the flow of sodium and chloride ions across the cell membrane. Most patients with CF (85%) carry mutations which are associated with pancreatic insufficiency. The clinical features of CF can be highly variable, including non-specific respiratory symptoms or gastrointestinal symptoms and malnutrition. In the past, growth failure and weight loss were seen as inevitable in the face of progressive lung disease. In 1988, Corey et al. [10] reported growth, pulmonary function and survival in 499 CF patients from Boston (USA) and 534 from Toronto (Canada) followed from 1972 to 1981. Although patients' characteristics were comparable in the two populations, height and weight percentiles were higher in patients from Toronto than in Boston and also their survival (30 vs. 21 years). The only difference was that Canadian patients had a better nutritional status resulting from a non-restricted dietary fat diet and the use of coated pancreatic enzymes. Since that report, many studies have shown that nutritional status during childhood is the most important single factor determining pulmonary status (and hence likely survival) in CF individuals. In order to achieve the most favorable outcomes, the care of children with CF should address both nutritional status and lung function. Normal growth, therefore, has been decreed by Cystic Fibrosis Foundation (CFF) as the key goal of nutritional support in children with CF [11] . Nutritional status by all parameters (wasting, stunting, body composition) has been shown to affect lung function and survival in patients with CF in many studies before and this year too As children get older, the nutrient requirements increase, but progression of lung disease compromises nutritional status by increasing daily energy demands, interfering with appetite, and resulting in a decreased overall energy intake. Many studies have shown that growth deviation takes place during the puberty years as patients with CF have delayed puberty and diminished growth pubertal spurt (cf. Zhang et al., Bournez et al.). This maturational delay affects negatively final adult height, as 70-80% of children with CF did not reach their genetic potential. Growth delay and deficit do not affect only the final adult height but also survival, as shown in the study by Vieni et al.
Evaluation of nutritional intake and growth must be made at every visit. Every effort should be made to maintain ideal body weight (IBW%) in children <2 years (>95%) and BMI in children >2 years (ideally >50th percentile). BMI is an easy, quick, safe, and low-cost method that is considered the gold standard to approach nutritional status in children with CF >2 years. Data from the CFF Registry has consistently demonstrated a positive association between BMI and lung function. Several studies have also explored the relationship between BMI and lean muscle mass and measures of disease severity in CF. Engelen et al. have shown that FFM depletion is prevalent and not always detected using BMI%, furthermore, FFM was correlated with FEV1 (a measure of lung function). Using the data from CF Twin-Sibling Study and Cystic Fibrosis Foundation Patient Registry, the original study of Bradley et al. had evaluated the relative contribution of genetic modifiers to the nutritional status of young children with CF. Linkage analyses pointed that genes on chromosomes 1 and 5 significantly influence the BMI variation in children with CF. The search for CF-modifying genes represents the opportunity to further insight into the pathophysiology of malnutrition in children with CF and discovery of potential new targets for nutritional intervention.
There is evidence that nutritional support can delay the decline in lung function, translating into improved health, quality of life, and length of survival in these patients. Studies in the early 1980s, which reported positive effects of dietary counseling and/or supplements, were however conducted in patients who had been placed on a low-fat diet before the study. The recent Cochrane systematic review (cf. Smyth and Walters), however, reported no improvement in nutritional parameters or pulmonary function in children with CF on oral nutritional supplements. Enteral tube feeding, using gastrostomy, usually delivered as overnight feeds with appropriate enzyme therapy, may provide approximately 30-50% of estimated daily energy requirements. Supplemental gastrostomy feedings were shown to be associated with improvements in weight and height percentiles for age, increases in percent of body fat and fat-free mass and sustained growth. The retrospective study of Bradley et al. however reported no effect on pulmonary function status or disease severity (hospitalizations). Currently, most studies on supplemental gastrostomy feedings are, however, retrospective and since randomization is not feasible/ethical, only cohort longitudinal studies at best will be expected. Use of rhGH for the treatment of growth deficit as well as an anabolic agent has been addressed by several studies. A systematic review published in 2010 which evaluated 10 controlled clinical trials and 8 observational studies showed that in the controlled trials, markers of pulmonary function, anthropometrics, and bone mineralization appeared to be increased compared with controls [12] . With regard to long-term health issues, such as pulmonary exacerbations, hospitalizations, or mortality, the only significant finding was that GH therapy seemed to reduce the rate of hospitalizations. The recent Cochrane systematic review (cf. Thaker et al.) which included 4 RCTs found only modest improvements in anthropometric measures (height, weight, height and weight velocity and lean tissue mass) but no evidence of better pulmonary function, reduced morbidity or improved quality of life. According to CFF nutrition consensus, children and adolescents with CF are expected to experience typical growth when appropriate nutrition and pancreatic enzyme replacement therapy are provided. In 2008, nutritional recommendations for infants and children with CF provided evidence-based and consensus recommendations for many aspects of nutrition in CF patients [3] . Unfortunately, good quality evidence to support precise nutrition recommendations for patients with CF is missing, although efforts have been made to use available evidence to set care standards. Moreover, the benefit of providing invasive nutrition besides improving the patient's nutritional status and growth is questionable in terms of survival and lung function. In general, awareness of clinic staff about the overall nutritional status of their patient population and timely nutritional support when clinical indices fall below standards should be standard of care [13] .
Cerebral Palsy
Energy requirements in preschool-age children with cerebral palsy 
Aims:
The study aimed to evaluate the energy requirements (ER) in a group of children with cerebral palsy (CP) using the doubly labeled water (DLW) method. The authors compared measured ER among children with CP and different functional abilities or motor dysfunction with typically developing children (TDC) and published estimation equations. Methods: The study enrolled and evaluated 32 children with CP and 16 typically developed children (TDC) aged 2.9-4.4 years. Children with disorders or children on medications known to affect growth or metabolism were excluded from the study. Each child was given a dose of oxygen-18 and deuterium water (1.25 g/kg 10% H 2 18 O and 0.05 g/kg 99.8% 2H 2 O). A single urine sample was collected at baseline, daily urine samples were examined thereafter for 10 days. The production rate of carbon dioxide was calculated as the difference between the elimination rates of deuterium and oxygen-18 in conjunction with their dilution space. Oxygen consumption was determined by assuming a respiratory quotient of 0.85, and TEE was calculated using Weir equation [14] . Anthropometric measurements included weight, height/length/knee height. Functional ability (Gross Motor Function Classification System -GMFCS) and motor dysfunction type and distribution were evaluated using internationally accepted and validated criteria and classifications. Results: The children with CP were shorter, lighter, and had lower free-fat mass indexes (FFMIs) than did the TDC (p < 0.01). Mean height z-scores and FFMI for children with CP decreased as ambulatory status declined (p < 0.05). Children with CP had significantly lower energy requirements (ERs) than did TDC [p < 0.001; mean difference (MD) = 1212kJ/d]. Ambulant CP children had, on average, an ER that was 16% lower than that of TDC. Marginally ambulant and non-ambulant children had an ER that was 31% lower than that of TDC and 18% lower than that of ambulant CP children. No statistical difference in ERs was found between ambulant children and TDC. The difference in GMFCS were responsible for 67% of the variability in ER (r 2 = 0.67). The FFM of the children contributed most to ERs variability. Correlation analyses of variables known to con-tribute to ERs showed that ERs were strongly positively correlated with FFM, weight, and height. When the influence of functional ability in the children with CP was considered, ERs decreased with increasing severity of disability (marginally ambulant and non-ambulant children had lower ER than did ambulant children). The estimated ERs from Rieken et al. [15] models were significantly less than the measured ER values, with a consistent bias of -1089kJ, representing an underestimation in ERs in the current population of 22%.
Conclusions:
The results of this study confirm that ER recommendations, equations and energy intakes of typically developed children are not valid for use in children with CP, especially in more affected children. Motor disability (ambulation vs. non-ambulation) and FFM explained about 67% of the variability in ERs in this group of children with CP.
Validation of a modified three-day weighed food record for measuring energy intake in preschool-aged children with cerebral palsy 
Aims:
The aim of the current study was to validate the use of a modified 3-day weighed food record for measuring energy intake (EI) in a population of young children with CP. Methods: The study included children aged between 35 and 54 months with a diagnosis of CP living in the community in the State of Queensland, Australia, and compared them to typically developing children (TDC) in the same age range residing in the same area. The children underwent the following evaluations: anthropometry measurements, functional ability using the Gross Motor Function Classification System (GMFCS) [16] , energy assessment by a 3-day weighed food record, total energy expenditure (TEE) using the doubly labeled water (DLW) technique and oral motor and swallowing skills rating using the Feeding and Swallowing Competency Subset of the Dysphagia Disorders Survey for Paediatrics [17] . Validation of the 3-day weighed food record was done by comparing reported EI to measures of TEE for each individual child over the 10-day data collection period and the difference between reported EI and measured TEE (when expressed as a percentage of TEE) was less than 19%, an EI/TEE ratio of 1.00 indicating perfect reporting. Results: The study population included 31 children (61% male) with CP aged from 2.9 to 4.4 years and 15 TDC (63% male) aged from 3.0 to 4.5 years. 13 children (42%) had moderate to severe feeding problems and 11/13 of these children were classified as GMFCS III, IV or V. Six children (19%) were tube-fed, all classified as GMFCS level V. In general, children with CP were shorter and lighter than the TDC. EI was statistically significantly less than TEE values for the children with CP as a total population and for the TDC [4,628 ± 1,325 vs. 5,142 ± 1,265 kJ/day (p < 0.01) in CP children and 5,310 ± 864 vs. 6,397 ± 779 kJ/day (p < 0.01) in TDC]. Evaluation of the EI as a percentage of TEE for each group showed that children with moderate to severe CP had the most accurate reporting with a result of 4.3%. On average, 75% of the children with CP had EI results that were within 20% of their TEE values. The study showed no substantial overreporting as reported in previous literature. Considering functional ability, in children with moderate to severe CP the ratio of EI/ TEE was 0.96 indicating greater accuracy compared to the TDC (0.83). Considering the influence of feeding method on the accuracy of reporting showed that orally-fed children displayed more accurate reporting when compared to those who were tube-fed, evidenced by a very low EI/TEE ratio of 1.01 indicating nearly perfect reporting. Conclusions: Evaluation of 3-day weighed food record for assessment of energy intake in children with CP is a valid tool in pre-schoolchildren with CP among all the levels of functional ability and feeding difficulties or methods. The findings from this study are in contrast to previous literature reported by Stallings et al. [18] that reported gross overestimation of EI in school-aged children with CP.
The use of bioelectrical impedance analysis to estimate total body water in young children with cerebral palsy
Bell KL [1] [2] [3] [4] 
Aims:
The study aimed to evaluate: (1) the reliability of body impedance (BIA) measurements in young children with cerebral palsy (CP) across different grades of motor severity, (2) appropriate electrodes' placement for BIA in children with CP and unilateral involvement, (3) the best equation for the calculation of total body water (TBW) from the BIA in pre-school children with CP. Methods: The study included 55 preschool children aged 2.40 ± 0.59 with CP and different ranges of Gross Motor Function Classification System (GMFCS) levels. Impedance (ohm) and TBW were measured and TBW was estimated from impedance using three previously published equations [19] [20] [21] . These equations were selected as they were all developed in groups containing children of preschool age and are all based on BIA. Results: (1) Duplicate BIA measurements were performed in 50 children (91%) on the left-hand side of the body and 49 children on the right side. Duplicate measurements showed minimal differences: 0.5% variation on the left side of the body and 0.1% variation on the right side. However, there was a significant variation within some individuals and a third measurement was required in 44% measurements for the left-hand side and 35% occasions for the right-hand side of the body, since the duplicate measures were >5 ohm apart. (2) The mean differences of BIA results obtained from measurements conducted on either side of the body in young children with and without unilateral impairment were 1.2 and 0.8% respectively. (3) In children with bilateral impairment the estimated ± SD the mean of estimated and measures TBW ± SD were greatest for the Pencharz equations (10.4 ± 1.5 and 9.0 ± 1.4, respectively) and lowest for the Fjeld equation (7.6 ± 1.1 and 7.6 ± 1.2, respectively). In children with unilateral impairment, estimated TBW was lowest on the impaired compared to the unimpaired sides of the body for all three equations. Mean differences between the impaired and unimpaired sides were: for the Methods: This was a retrospective, cross-sectional study which reviewed the pre-and post-gastrostomy weight and health outcome (hospitalization days) in 24 children who had gastrostomy placed before the age of 18 months and 17 children who had the gastrostomy placed after the age of 18 months. Results: The mean weight pre-gastrostomy z-score in the <18 month group was -2.78 SD and -1.17 SD in the >18 month group. The mean weight post-gastrostomy z-score in the <18 month group was -1.45 SD and -0.72 SD in the >18 month group. The weight pre-gastrostomy z-score was significantly lower in the younger age group (p = 0.014), however there was no significant difference in z-score between the groups post-gastrostomy (p = 0.178). The mean difference in the z-score pre-and post-gastrostomy was significantly greater in the younger age group than in the older group (p = 0.021). There was no significant difference in the hospital admission rates pre-and postgastrostomy in the early or the late group.
Conclusions:
The results of the study shows that gastrostomy use for nutritional support improved weight gain at any age, but younger children achieved greater weight gain.
gastrostomy tube placed (22% in Sweden to 3% in Iceland). Gastrostomy feeding was given to 67% of children with GMFCS level IV and V in western Sweden, but only to 12% of children in Portugal. Median age at placement of gastrostomy was 22 months (range 1-120). The median age range between different countries was 16 months in western Sweden (5-108 months) to 70 months in northern England (12-120 months). The mean z-scores for weight was -0.86 (SD 1.71) and -0.87 for height (SD 1.50). In children in GMFCS level IV and V, there were significant differences in z-scores for weight and height between the areas. Portuguese children had lower weight z-scores compared with Norwegian, Swedish and Danish children (p < 0.001), while their height z-scores were lower only compared with Swedish and Danish children (p = 0.002). For children in GMFCS levels I and II, no significant differences in weight (p = 0.114) or height (p = 0.472) z-scores were observed between the different populations. The differences in z-scores between the countries were more marked when using the WHO growth references and also resulted in statistically significant differences for height z-scores between countries among children in GMFCS levels I and II. Conclusions: The study showed considerable variations in the prevalence of growth restriction, feeding difficulties and the use of GTF in children with CP across different areas in six European countries. The differences were even more marked in children with GMFCS levels IV and V, the group most likely to have associated feeding difficulties. Among these children, those living in areas where GTF was less used were more growth-restricted than children in countries where GTF was more prevalent. This study outlines the lack of clear guidelines and differences in the decisionmaking with regard to nutritional support of children with CP in different centers.
Comments Children with neurologic disabilities present complex management challenges, both for their families and for the professionals involved in their care. Growth retardation and feeding disorders are common in these children and represent a particular challenge to clinicians providing nutritional support. The first difficulty to face is to accurately assess the child's height and weight, which may not be possible using standard methods; therefore, proxies such as arm span or knee height may be required. The second challenge is to correctly assess their energy and nutrient needs to avoid overor underprovision of nutrients. The single previous study that evaluated the EI in children with CP reported 44-54% overestimation compared to TEE data [18] . These differences could be explained by different populations or accuracy of food intake assessment and reporting. The significance of these discrepancies is that nutrition support should be based on objective and individualized evaluation in each child with CP, as generalizing data from different studies or populations may be subject to large deviations from the actual requirements. Historical cohorts demonstrate significant levels of malnutrition, however the clinician has to be aware that some children may not follow a standard growth trajectory and follow a growth trajectory set by their own genetic potential/disease. Several studies have shown that body composition and resting energy expenditure (REE) is variable in children with cerebral palsy (CP) and are affected by multiple factors (functional capacity, degree of mobility, severity of disease, level of altered metabolism disease, medication, type of feeding, etc. Birth Cohort Study. Growth trajectories were modeled using mixed-effects models to take into account the within-subject correlation of head and body sizes. Results: A total of 376 children in the study sample (106,082 children) had been diagnosed with ASD (310 boys and 66 girls). The mean birth HC in boys was not different in children with or without ADS. The mean HC in boys was similar after birth in cases and non-cases (HC mean difference <0.1 cm), but the variability of HC was greater in cases and there was an increase in the proportion with macrocephaly in ASD boys by age 12 months, to 8.7% (4.7-14.4%). The difference between cases and non-cases in girls reached 0.5 cm at 12 months of age. Adjustment for covariates attenuated the difference to 0.2 cm at 12 months. Boys with ASD had similar lengths to non-cases at birth, but grew faster after birth and were taller by 0.5 cm at 6 months and 1.1 cm at 12 months, but the mean difference reverted to 0.6 cm by age 3 years. In girls with ASD the mean birth length was 0.64 cm lower than the mean for girls without ASD but the differences in means were smaller at other ages. The birth weight of boys with ASD was similar to birth weight in non-cases, but after birth, ASD boys had a more rapid increase in mean weight and were on average about 300 g heavier than other boys from age 12 months. In girls with ASD, mean birth weight was lower than the mean for other girls and continued to be 150-350 g lower up to age 3 years, but the difference in means largely disappeared after adjustment for covariates. Boys with ASD had similar mean BMIs to other boys at all ages. Girls with ASD had somewhat lower mean BMIs throughout, as a result of their lower mean weight, although the 95% CIs were always overlapping with those of non-cases. Conclusions: Growth trajectories for HC, length and weight in children with ASD were different from those of other children and the differences are sex-specific. Boys showed higher prevalence of macrocephaly and increased mean length and weight up to 12 months. For girls with ASD, the reductions in length, weight, and HC were attenuated by adjustment for covariates.
Nutrition, physical activity, and bone mineral density in youth with autistic spectrum disorders Aims: The aim of the study was to (1) assess the nutritional intake of children with ASDs, (2) evaluate bone mineral density (BMD) in a sample of 10-to 18-year-olds with ASDs, and (3) correlate medical history and body mass index (BMI), diet, activity, and parental perceptions of lifestyle with BMD. Methods: The study included 26 children aged 10-18 years with ASDs. Anthropometries, Tanner stage, medication and medical diagnoses ware collected by parent interview and from the clinic record. Parents were asked to rate their child's dietary habits, their average physical activity level and to estimate the sunlight exposure in a typical week. Dual-energy x-ray absorptiometery (DXA) was used to measure BMD of the lumbar spine (L1-L4). Laboratory tests included serum 25-OHD, alkaline phosphatase, parathyroid hormone, erythrocyte indices, electrolytes, liver and renal function tests, thyroid-stimulating hormone, and free T 4 . Results: There were 21 males (80.8%) and 5 females (19.2%) aged from 10.3 to 18.2 years (mean 13.4). Mean body mass index (BMI) percentile was 47.9 (SD 36.37, range 1st to 99th), 27% of participants were overweight, while 23% were underweight. Food diaries indicated that participants' the importance of nutritional surveillance in primary care for all children, especially children with ASDs. The best way to achieve that is periodic dietary assessment corroborated with anthropometric and laboratory data, and consideration of referral to a registered dietitian.
Aims:
The study aims were to determine the prevalence of iron deficiency in children with ASD and evaluate the iron intake, and the relationship of iron intake to iron status. Methods: The study population was recruited among children treated at five Autism Treatment Network (ATN) sites. Parents completed a 3-day food record containing all foods, beverages, and supplements ingested by the child over 3 consecutive days. Laboratory tests included complete blood count, serum ferritin (SF), transferring saturation (TS), iron, and total iron-binding capacity (TIBC). Results: Iron status was evaluated in 222/368 (60%, mean age 5.3 years, range 2-11) children with ASDs enrolled in the Diet and Nutrition Study. Low iron stores were found in 8% of children (SF <12 ng/ml). One child had IDA. ID rates were lower in all age groups of children with ASDs, compared with NHANES data. The percentage of children with iron intakes less than EAR was 2% and increased with age. Children with ASD did not differ from the NHANES population in iron intake. The major sources of iron in the diet of these children were from enriched or fortified foods, such as breakfast cereals. Conclusions: Children with ASD have low iron intakes and are at risk for low SF. Taking into consideration the important consequences of iron deficiency on developmental and behavioral function in infants and children, dietary history and screening for iron stores should be considered in children with ASD and inadequate iron intake.
Comments Autism spectrum disorders (ASD) are neurodevelopmental disorders characterized by impaired social and communication interactions as well as limited, repetitive interests and behavior. The longitudinal population-based Norwegian registry reported that children with ASD also have different growth trajectories when compared to other children. Conventional treatment is based on the combination of behavioral and pharmacotherapy. Dietary manipulations are frequently adopted by families of children with ASD seeking to improve their children behavior. Dietary manipulations in conjunction with children's peculiar feeding habits may easily result in multiple nutritional deficiencies, undernutrition or overweight and poor bone status, as illustrated by the studies published this last year. An important part of autism children's care is evaluation and support of patient's nutritional status to prevent further neurological and behavior deterioration as a result of nutritional deficiencies. Many studies have shown the need to supplement the missing nutrients from the diets of autistic patients with fatty acids omega-3, probiotics, vitamins and minerals. Adopted diets should take into consideration nutritional requirements and food preferences of the patient. It is important to emphasize that continual monitoring of the diet and nutritional status of children with ASD is required. Parents and caregivers should be aware of the benefits and dangers of nutritional manipulations and the need for proper monitoring of diet and growth of children with ASD.
Decrease in bone mineral density and the increased risk of spontaneous fractures are some of the most important medical consequences of AN. To this we should add growth retardation and lower final adult height, as shown by the study by of ModanMoses et al. The treatment of AN should therefore aim not only at fast recovery but also to prevent and treat the long-term effects of this disorder. Monitoring GH levels at admission and during refeeding in patients suffering from AN was shown to have some prognostic value. The role of this factor in the disease is however, probably indirect, reflecting specific changes associated with the adapted response to starvation. Further investigations of the long-term disease risk of relapse and the approach to their prevention and treatment are needed.
